| http://purl.uniprot.org/citations/23555949 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/23555949 | http://www.w3.org/2000/01/rdf-schema#comment | "We examined anti-tumor effects of zoledronic acid (ZOL), one of the bisphosphonates agents clinically used for preventing loss of bone mass, on human mesothelioma cells bearing the wild-type p53 gene. ZOL-treated cells showed activation of caspase-3/7, -8 and -9, and increased sub-G1 phase fractions. A combinatory use of ZOL and cisplatin (CDDP), one of the first-line anti-cancer agents for mesothelioma, synergistically or additively produced the cytotoxicity on mesothelioma cells. Moreover, the combination achieved greater anti-tumor effects on mesothelioma developed in the pleural cavity than administration of either ZOL or CDDP alone. ZOL-treated cells as well as CDDP-treated cells induced p53 phosphorylation at Ser 15, a marker of p53 activation, and up-regulated p53 protein expression levels. Down-regulation of p53 levels with siRNA however did not influence the ZOL-mediated cytotoxicity but negated the combinatory effects by ZOL and CDDP. In addition, ZOL treatments augmented cytotoxicity of adenoviruses expressing the p53 gene on mesothelioma. These data demonstrated that ZOL-mediated augmentation of p53, which was not linked with ZOL-induced cytotoxicity, played a role in the combinatory effects with a p53 up-regulating agent, and suggests a possible clinical use of ZOL to mesothelioma with anti-cancer agents."xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.org/dc/terms/identifier | "doi:10.1371/journal.pone.0060297"xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/author | "Jiang Y."xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/author | "Kobayashi H."xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/author | "Okamoto S."xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/author | "Shimada H."xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/author | "Tatsumi K."xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/author | "Tada Y."xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/author | "Takiguchi Y."xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/author | "Kawamura K."xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/author | "Tagawa M."xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/author | "Hiroshima K."xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/author | "Fukamachi T."xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/author | "Shingyoji M."xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/date | "2013"xsd:gYear |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/name | "PLoS One"xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/pages | "e60297"xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/title | "Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels."xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://purl.uniprot.org/core/volume | "8"xsd:string |
| http://purl.uniprot.org/citations/23555949 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/23555949 |
| http://purl.uniprot.org/citations/23555949 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/23555949 |
| http://purl.uniprot.org/uniprot/#_P04637-mappedCitation-23555949 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/23555949 |
| http://purl.uniprot.org/uniprot/P04637 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/23555949 |